News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

PledPharma will be presenting company’s drug development programs at today’s CMD in Stockholm

March 26, 2019

Stockholm, March 26, 2019. PledPharma AB (publ) hosts today the company’s capital markets day (CMD) in Stockholm, where it will be presenting company’s development programs, including opportunities for indication expansion of PledOx® and the results from Aladote®’s POP study.

PledPharma is an innovative, unique and integrated pharmaceutical drug development company, focusing on improving treatments for diseases with substantial unmet medical need. The company hosts today a capital markets day for analysts, investors and media in Stockholm, Sweden.
Members from the management team and two key opinion leaders (KOL) will be presenting company’s drug development programs PledOx® and Aladote®. Broader presentation regarding unmet medical need, the development programs, commercial potential including opportunities for indication expansion of PledOx® will be presented.

Speakers at the CMD include the Chairman of the Board, Håkan Åström, the CEO, Nicklas Westerholm and members from the management team as well as two key opinion leaders, Dr. James Dear, Edinburgh University and Prof. Per Pfeiffer, Odense University. Lars Hevreng, head of research at Vator Securities and previously healthcare analyst will moderate the event.

Venue details:
Time: Tuesday March 26th, at 10:00-15:00 CET
Venue: Redeye, Mäster Samuelsgatan 42, 10th floor, Stockholm
Presentations will be held in English.
The CMD will be broadcasted live at



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10